

Supplementary Materials

1-[5-(4-Tolyl)-1,3,4-oxadiazol-2-yl]methanamine

Ganesh Shimoga, Eun-Jae Shin and Sang-Youn Kim*

Interaction Laboratory of Advanced Technology Research Center, Korea University of Technology and Education,
1800 Chungjeollo, Byeongcheon-myeon, Cheonan city 330-708, South Korea; icganeshin@gmail.com (G.S.);
ejshin@koreatech.ac.kr (E.-J.S.); sykim@koreatech.ac.kr (S.-Y.K.)

* Correspondence: sykim@koreatech.ac.kr; Tel.: +82-41-560-1461.




Figure S1. ¹H-NMR spectra of 1-[5-(4-tolyl)-1,3,4-oxadiazol-2-yl]methanamine (Compound 3)




Figure S2. ^{13}C NMR spectrum of 1-[5-(4-tolyl)-1,3,4-oxadiazol-2-yl]methanamine (Compound 3)




Figure S3. LCMS spectra of 1-[5-(4-tolyl)-1,3,4-oxadiazol-2-yl]methanamine (Compound 3)




Figure S4. FTIR spectrum of 1-[5-(4-tolyl)-1,3,4-oxadiazol-2-yl]methanamine (Compound 3)




Figure S5. DSC spectrum of 1-[5-(4-tolyl)-1,3,4-oxadiazol-2-yl]methanamine (Compound 3)




Figure S6. UV-vis spectrum of 0.001 M solution of 1-[5-(4-tolyl)-1,3,4-oxadiazol-2-yl]methanamine (Compound 3) in (a) *N,N*-Dimethylformamide (b) Ethyl alcohol (c) Tetrahydrofuran.